Steven Steinhubl, MD
Director, Digital Medicine, Scripps Translational Science Institute
Cardiologist, Scripps Health
Dr. Steinhubl is the Director of Digital Medicine at STSI and a cardiologist at Scripps Health, Scripps Clinic. He received his undergraduate training in chemical engineering at Purdue University in Indiana, graduate training in physiology at Georgetown University in Washington, DC, and his medical degree at St. Louis University in Missouri. Steve’s internal medicine residency training was completed at David Grant Medical Center at Travis Air Force Base, California. Following residency, he was a staff internist at Elmendorf Air Force Base Hospital in Anchorage, Alaska. His cardiology and interventional cardiology fellowships were at the Cleveland Clinic Foundation where he was also Chief Cardiology Fellow. Prior to joining Scripps Steve was the Director of Cardiovascular Wellness and the Medical Director for Employee Wellness for the Geisinger Healthcare System. He was also the Cardiology Fellowship Director, a clinician-scientist and a staff cardiologist there. In the past, beyond his time in the Air Force, Steve has also been a Global Medical Vice-President for The Medicines Company based in Zurich Switzerland and the Director of Cardiovascular Education and Clinical Research at the University of Kentucky in Lexington.
Dr Steinhubl’s research activities have covered a broad range of topics in cardiology with a primary early focus on trials of novel antithrombotic therapies for the treatment and prevention of cardiovascular disease, and more recently on the application of an integrated systems-based approach to the optimal identification, communication and treatment of an individual’s risk for various manifestations of cardiovascular disease. He has been principal investigator or helped lead over a dozen large-scale, international randomized trials and has authored over 200 peer-reviewed manuscripts as well as numerous book chapters, and abstracts.
Eric J. Topol, MD
Founder & Director, Scripps Translational Science Institute
Executive VP & Professor, Molecular Medicine, The Scripps Research Institute
Eric Topol is Executive VP and Professor of Molecular Medicine at The Scripps Research Institute (TSRI), and the Founder and Director of the Scripps Translational Science Institute (STSI). As a researcher, he has published over 1100 peer-reviewed articles, with more than 170,000 citations, elected to the National Academy of Medicine, and is one of the top 10 most cited researchers in medicine (Thomson Reuters ISI, “Doctor of the Decade”). His principal scientific focus has been on the genomic and digital tools to individualize medicine—and the power that brings to individuals to drive the future of medicine.
In 2016, Topol was awarded a $207M grant from the NIH to lead a significant part of the Precision Medicine Initiative, a one million American All of Us prospective research program. Prior to coming to lead STSI in 2007, for which he is founder and principal investigator of a flagship $33M NIH grant, he led the Cleveland Clinic to become the #1 center for heart care and was the founder of a new medical school there. He has been voted as the #1 most influential physician leader in the United States in a national poll conducted by Modern Healthcare. Besides editing several textbooks, he has published two bestseller books on the future of medicine: The Creative Destruction of Medicine and The Patient Will See You Now.
Andrew Marshall, PhD
Chief Editor, Nature Biotechnology
Andrew Marshall was appointed Chief Editor of Nature Biotechnology in 2000 after joining the journal in 1996. Since that time, the journal’s impact factor has increased from 11.0 to 43.1. As well as frequently speaking about biotechnology research and translation at conferences, he also organizes meetings and symposia. Previously, he was Editor of Current Opinion in Biotechnology. He has written hundreds of articles and editorials in the trade and popular media, including The Economist and Popular Science. He has pioneered networking events termed SciCafés in Boston, San Francisco, New York, San Diego, Houston, London and Singapore, which showcase rising stars in academia to early-stage investors and industry R&D leaders. He obtained a BSc with Honors and his PhD and postdoctoral experience in molecular biology and microbiology at King’s College London, where he was given the Helen White Prize, likely as a result of a clerical error.